Table 2

Responsiveness of individual items and indices ranked by t value in the Infliximab Multinational Psoriatic Arthritis Controlled Trial

	Active drug					Placebo					t Value
	Baseline	Mean Δ	SE_Δ	SRM	ES	Baseline	Mean Δ	SE_Δ	SRM	ES	t Value
CRP, C reactive protein; DAS, Disease Activity Score; ES, effect size; ESR, erythrocyte sedimentation rate; GST, global statistical test; HAQ, Health Assessment Questionnaire; Mean Δ, mean change; MS, morning stiffness; PASI, Psoriasis Area and Severity Index; PhGA, physician global assessment; PtGA, patient global assessment; RAI, Ritchie Articular Index; SE_Δ, standard error of mean change; SJC, swollen joint count; SRM, standardised response mean; TJC, tender joint count.
GST	–	460	16.2	3.96	–	–	226	14.9	2.15	–	10.6
DAS28 (0–10)	5.5	−2.6	0.2	−1.87	−2.30	5.4	−0.2	0.1	−0.21	−0.20	9.8
PhGA (0–100)	53.6	−33.9	3.2	−1.49	−1.84	52.4	0.3	2.4	0.02	0.01	8.5
DAS (0–10)	4.1	−1.9	0.2	−1.77	−2.13	3.9	−0.1	0.2	−0.13	−0.15	8.2
Pain (0–100)	53.4	−31.1	3.1	−1.40	−1.46	56.0	−0.1	2.8	−0.01	0.00	7.3
PtGA (0–100)	52.4	−27.6	3.2	−1.21	−1.18	56.0	1.0	3.1	0.05	0.05	6.4
TJC68 (0–68)	23.7	−13.1	1.6	−1.14	−0.96	20.4	0.8	1.7	0.07	0.07	6.0
ESR (mm/h)	32.7	−24.3	2.8	−1.24	−1.10	29.5	−4.6	1.9	−0.34	−0.24	5.7
TJC28 (0–28)	10.6	−6.2	0.7	−1.14	−0.98	9.7	−0.11	0.8	−0.02	−0.02	5.4
MS (min)	125.8	−91.5	21.9	−0.59	−0.59	149.9	−24.1	28.1	−0.12	−0.09	5.0
SJC66 (0–66)	14.6	−9.7	1.2	−1.15	−1.27	14.7	−1.0	1.3	−0.11	−0.14	5.0
HAQ (0–3)	1.15	−0.56	0.07	−1.18	−0.79	1.18	−0.01	0.04	−0.03	−0.01	4.8
SJC44 (0–44)	11.9	−7.7	1.0	−1.08	−1.26	11.7	−1.0	1.1	−0.13	−0.14	4.7
RAI (0–75)	13.5	−6.7	0.8	−1.19	−0.86	11.8	−0.2	1.3	−0.02	−0.02	4.3
SJC28 (0–28)	8.7	−5.7	0.9	−0.93	−1.13	9.1	−1.3	0.8	−0.21	−0.23	3.8
PASI (0–72)	5.1	−4.1	0.8	−0.82	−0.69	4.2	0.6	0.4	0.22	0.11	2.6
CRP (mg/l)	21.7	−11.3	3.4	−0.61	−0.57	31.1	−8.9	3.3	−0.40	−0.37	0.6